在阿尔茨海默氏病中,c-Abl氨酸激酶下调作为改善记忆的目标
Rilda León1, Daniela A Gutiérrez1, Claudio Pinto1
1Cell Signaling Laboratory, Department of Cellular and Molecular Biology, Biological Sciences Faculty, Millennium Institute on Immunology and Immunotherapy, Pontificia Universidad Católica de Chile, Santiago, Chile.
在阿尔茨海默病 (AD) 模型中抑制c-Abl激酶改善了认知功能并减少了AD病理. 作为c-Abl抑制剂的neurotinib显示出作为潜在的AD治疗的希望.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 非受体氨酸激酶c-Abl与阿尔茨海默氏症 (AD) 病原发生有关.
- 阿尔茨海默病小鼠模型 (APP/PS1) 显示认知能力下降.
研究的目的:
- 为了研究c-Abl对AD的APP/PS1小鼠模型认知衰退的影响.
- 评估在AD中抑制c-Abl的治疗潜力.
主要方法:
- 在大脑中对c-Abl进行条件遗传除 (c-Abl-KO).
- 药理上抑制c-Abl使用neurotinib,这是一个口服的大脑透抑制剂.
- 使用海马体依赖的任务 (物体位置,巴恩斯迷宫,记忆灵活性测试) 评估认知表现.
- 对粉样质斑块,星病和神经元保存的组织病理学分析.
主要成果:
- 接受c-Abl遗传剥离或神经丁治疗的小鼠在海马依赖的记忆任务中表现得更好.
- 抑制c-Abl导致粉样质斑块负荷降低,星质症降低,并保留了海马神经元.
- 在APP/PS1小鼠中,Neurotinib治疗加速了学习,改善了记忆灵活性.
结论:
- c-Abl在与AD相关的认知障碍中发挥着重要作用.
- 新型c-Abl抑制剂Neurotinib在阿尔茨海默病中显示出治疗潜力.
- 针对c-Abl是一个有前途的策略,用于开发新的AD治疗.
更多相关视频
06:23Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
相关概念视频
Alzheimer's Disease: Treatment
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
